Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to ...

Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

Ruxolitinib phosphate is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return. Invasive lobular carcinoma (ILC) – which ...

Auckland radiologist Dr Remy Lim is inviting Kiwis who’ve recently been diagnosed with lobular breast cancer to take part in a new clinical trial funded by Breast Cancer Foundation NZ.

"For close to six months, I could not walk without a cane, or I had to be pushed in a wheelchair or hold on to a friend, ...